Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Fan, Yuhua ^a   Chen, Meng ^a   Meng, Jia ^a   Yu, Lei ^a   Tu, Yingfeng ^a   Wan, Lin ^a   Fang, Kun ^a   Zhu, Wenliang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; PROTEIN LC3; REACTIVE OXYGEN METABOLITE; RESVERATROL; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; ORGANOARSENIC DERIVATIVE; OXIDE; STILBENE DERIVATIVE; TUMOR PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; AUTOPSY; CARDIOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MUSCLE CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; DRUG SCREENING; HEART MUSCLE CELL; LEUKEMIA, PROMYELOCYTIC, ACUTE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MYOCYTES, CARDIAC; NEOPLASM PROTEINS; OXIDES; RATS; REACTIVE OXYGEN SPECIES; STILBENES; SUPEROXIDE DISMUTASE;

EID: 84922132337     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105890     Document Type: Article

References (41)

1. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, et al. (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348. (Pubitemid 28509343)
2. Fox E, Razzouk BI, Widemann BC, Xiao S, O'Brien M, et al. (2008) Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood 111: 566-573.
3. Mathews V, Chendamarai E, George B, Viswabandya A, Srivastava A (2011) Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide. Mediterr J Hematol Infect Dis 3: e2011056.
4. Barbey JT, Pezzullo JC, Soignet SL (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21: 3609-3615. (Pubitemid 46594053)
5. Drolet B, Simard C, Roden DM (2004) Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 109: 26-29. (Pubitemid 38056016)
6. Mumford JL, Wu K, Xia Y, Kwok R, Yang Z, et al. (2007) Chronic Arsenic Exposure and Cardiac Repolarization Abnormalities with QT Interval Prolongation in a Population-based Study. Environ Health Perspect 115: 690-694. (Pubitemid 46785037)
7. Vizzardi E, Zanini G, Antonioli E, D'Aloia A, Raddino R, et al. (2008) QT prolongation: a case of arsenical pericardial and pleural effusion. Cardiovasc Toxicol 8: 41-44.
8. Ducas RA, Seftel MD, Ducas J, Seifer C (2011) Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia. J R Coll Physicians Edinb 41: 117-118.
9. Li Y, Sun X, Wang L, Zhou Z, Kang YJ (2002) Myocardial toxicity of arsenic trioxide in a mouse model. Cardiovasc Toxicol 2: 63-73. (Pubitemid 37070573)
10. Hirano S, Cui X, Li S, Kanno S, Kobayashi Y, et al. (2003) Difference in uptake and toxicity of trivalent and pentavalent inorganic arsenic in rat heart microvessel endothelial cells. Arch Toxicol 77: 305-312. (Pubitemid 36819260)
11. Hwang JT, Kwon DY, Park OJ, Kim MS (2008) Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes Nutr 2: 323-326. (Pubitemid 351447706)
12. Manna P, Sinha M, Sil PC (2008) Arsenic-induced oxidative myocardial injury: protective role of arjunolic acid. Arch Toxicol 82: 137-149.
13. Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, et al. (2001) Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 89: 279-286. (Pubitemid 34132687)
14. Pereira GC, Silva AM, Diogo CV, Carvalho FS, Monteiro P, et al. (2011) Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. Curr Pharm Des 17: 2113-2129.
15. Zhang W, Guo C, Gao R, Ge M, Zhu Y, et al. (2013) The Protective Role of Resveratrol against Arsenic Trioxide-Induced Cardiotoxicity. Evid Based Complement Alternat Med 2013: 407839.
16. Fan Y, Wang C, Zhang Y, Hang P, Liu Y, et al. (2013) Genistein ameliorates adverse cardiac effects induced by arsenic trioxide through preventing cardiomyocytes apoptosis. Cell Physiol Biochem 31: 80-91.
17. Hollman PC, Katan MB (1999) Dietary flavonoids: intake, health effects and bioavailability. Food Chem Toxicol 37: 937-942. (Pubitemid 29481795)
18. Ravindranath MH, Muthugounder S, Presser N, Viswanathan S (2004) Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol 546: 121-165. (Pubitemid 40103418)
19. Sun W, Wang W, Kim J, Keng P, Yang S, et al. (2008) Anti-cancer effect of resveratrol is associated with induction of apoptosis via a mitochondrial pathway alignment. Adv Exp Med Biol 614: 179-186.
20. Lee J, Giordano S, Zhang J (2012) Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J 441: 523-540.
21. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, et al. (1991) NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080-1086.
22. Chu W, Li C, Qu X, Zhao D, Wang X, et al. (2012) Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome. Cardiovasc Res 96: 90-98.
23. Ghaffari SH, Bashash D, Dizaji MZ, Ghavamzadeh A, Alimoghaddam K (2012) Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multitarget action. Tumour Biol 33: 157-172.
24. Park SY, Sohn UD (2011) Inhibitory effect of rosiglitazone on the acid-induced intracellular generation of hydrogen peroxide in cultured feline esophageal epithelial cells. Naunyn Schmiedebergs Arch Pharmacol 383: 191-201.
25. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-81.
26. Jiang S, Zu Y, Fu Y, Zhang Y, Efferth T (2008) Activation of the mitochondria driven pathway of apoptosis in human PC-3 prostate cancer cells by a novel hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel. Int J Oncol 33: 103-111.
27. Gao F, Yi J, Yuan JQ, Shi GY, Tang XM (2004) The cell cycle related apoptotic susceptibility to arsenic trioxide is associated with the level of reactive oxygen species. Cell Res 14: 81-85. (Pubitemid 43231834)
28. Heiss EH, Schilder YD, Dirsch VM (2007) Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells. J Biol Chem 282: 26759-26766. (Pubitemid 47501966)
29. Ullah MF, Ahmad A, Zubair H, Khan HY, Wang Z, et al. (2011) Soy isoflavone genistein induces cell death in breast cancer cells through mobilization of endogenous copper ions and generation of reactive oxygen species. Mol Nutr Food Res 55: 553-559.
30. Liou GY, Storz P (2010) Reactive oxygen species in cancer. Free Radic Res 44: 479-496.
31. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, et al. (2007) Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 26: 1749-60. (Pubitemid 46624042)
32. Qian W, Liu J, Jin J, Ni W, Xu W (2007) Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. Leuk Res 31: 329-339. (Pubitemid 46073178)
33. Kanamori H, Takemura G, Goto K, Tsujimoto A, Ogino A, et al. (2013) Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Am J Pathol 182: 701-713.
34. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, et al. (2010) Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328: 240-243.
35. Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, et al. (2010) PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 18: 88-98.
36. Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, et al. (2003) Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 309: 1017-1026. (Pubitemid 37122632)
37. Sun W, Wang W, Kim J, Keng P, Yang S, et al. (2008) Anti-cancer effect of resveratrol is associated with induction of apoptosis via a mitochondrial pathway alignment. Adv Exp Med Biol 614: 179-186.
38. Nadal-Serrano M, Pons DG, Sastre-Serra J, Blanquer-Rosselló Mdel M, Roca P, et al. (2013) Genistein modulates oxidative stress in breast cancer cell lines according to ERα/ERβ ratio: effects on mitochondrial functionality, sirtuins, uncoupling protein 2 and antioxidant enzymes. Int J Biochem Cell Biol 45: 2045-2051.
39. Xuan W, Wu B, Chen C, Chen B, Zhang W, et al. (2012) Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine*. Crit Care Med 40: 3026-3033.
40. Kanamori H, Takemura G, Goto K, Tsujimoto A, Ogino A, et al. (2013) Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Am J Pathol. 182: 701-713.
41. Nencioni A, Cea M, Montecucco F, Longo VD, Patrone F, et al. (2013) Autophagy in blood cancers: biological role and therapeutic implications. Haematologica 98: 1335-1343.